CGRP monoclonal antibodies: erenumab
Evidence-based neurology checklist on cgrp monoclonal antibodies: erenumab: Dose and administration It is indicated if migraine frequency is at least four days a month The initial dose is 70mg SC monthly The dose may be increased 140mg monthly It should be allowed to warm up to temperature before…
Dose and administration
- It is indicated if migraine frequency is at least four days a month
- The initial dose is 70mg SC monthly
- The dose may be increased 140mg monthly
- It should be allowed to warm up to temperature before administration
General complications
Systemic complications
Acronym
References
- Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15:382-390.
- Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2017; 16:425-434.
- Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology 2017; 89:1237-1243.
- Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. NEJM 2017; 377:2123-2132.
- Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018; 38:1026-1037.
- And 8 more. Subscribe to see the full list
